Morgan Stanley Raises Price Targets on Biohaven and Allegion
Morgan Stanley lifted its Biohaven price target to $21 from $19 and Allegion's to $181 from $170, keeping both ratings. Source: Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Dow Jones Newswires, citing Benzinga, Morgan Stanley raised its Biohaven price target to $21 from $19 and kept its Overweight rating. For Allegion, the bank increased its target to $181 from $170 and maintained its Equal-Weight rating.
Both actions were recorded on November 3, 2026: the Biohaven update at 17:32 GMT and the Allegion update at 17:27 GMT.
why it matters
Price target changes and rating confirmations are routine analyst actions. They reflect one bank's assessment and rarely move quotes on their own, so their significance for the broader market is limited.
tags
instruments
sources
- Biohaven Price Target Raised to $21.00/Share From $19.00 by Morgan Stanley — Dow Jones Newswires, 3 November 2026 at 17:32 UTC
- Allegion Price Target Raised to $181.00/Share From $170.00 by Morgan Stanley — Dow Jones Newswires, 3 November 2026 at 17:27 UTC
- Neurocrine Price Target Raised to $185.00/Share From $183.00 by Morgan Stanley — Dow Jones Newswires, 3 November 2026 at 17:49 UTC
- World Kinect Price Target Raised to $32.00/Share From $30.00 by Morgan Stanley — Dow Jones Newswires, 3 November 2026 at 17:55 UTC
- Teledyne Price Target Raised to $725.00/Share From $715.00 by Morgan Stanley — Dow Jones Newswires, 3 November 2026 at 17:52 UTC
- Toll Brothers Price Target Raised to $170.00/Share From $159.00 by Morgan Stanley — Dow Jones Newswires, 3 November 2026 at 17:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗